"Safe" and "effective" are defined as follows: Safety is the condition of presenting a reasonably low risk of harm, injury, or loss when a technology is utilized in the specified indication; and effectiveness is the quality of producing a desired, beneficial effect under the conditions of actual use. The categories for response to a DATTA question are defined as follows: Established—a technology demonstrated and accepted as safe and effective by the practicing medical community; investigational—a technology largely confined to use under research protocol; unacceptable—the risk/benefit ratio is unfavorable; and indeterminate—the evidence is insufficient for a definitive decision, and no consensus exists to date; further study may be warranted.
For each question, the response category receiving the most votes was tested for a majority, assuming that the DATTA panel is a sample from a broader population of experts. By using exact binominal probabilities, the likelihood of the observed vote was calculated if exactly 50% of the total population of experts support that response for that question. Hence, the null hypothesis is that 50% of all experts support the response. Rejection of the null hypothesis, and acceptance of the alternative, is interpreted as evidence of a majority opinion in the total population of experts, and a consensus is achieved.
Poblete RB, Rodriguez K, Foust RT, Reddy KR, Saldana MJ. Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS) . Ann Intern Med . 1989;;110:737-738.
Dyner TS, Lang W, Busch DF, Gordon PR. Intravascular and pleural involvement by Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome (AIDS) . Ann Intern Med . 1989;;111:94-95.
ABD AG, Nierman DM, Ilowite JS, Pierson RN Jr, Bell AL Jr. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis . Chest . 1988;;94:329-331.
Centers for Disease Control. Mycobacterium tuberculosis: transmission in a health clinic—Florida, 1988 . MMWR . 1989;;38:256-258,263-264.
Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus . MMWR . 1989;;38(
(suppl 5)
):1-9.
Update AIDS Weekly Surveillance Report . Atlanta, Ga: Centers for Disease Control;
(February 1)
, 1988;.
Miller-Catchpole R, Variakojis D, Anastasi J, Abrahams C, and the Chicago Associated Pathologists. The Chicago AIDS autopsy study: opportunistic infections, neoplasms and findings from selected organ systems with a comparison to national data . Mod Pathol . 1989;;2:277-294.
Moss AR, McCallum G, Volberding PA, Bacchetti P, Dritz S. Mortality associated with mode of presentation in the acquired immunodeficiency syndrome . J Natl Cancer Inst . 1984;;73:1281-1284.
Rainer CA, Feigal DW, Leoung G, Clement M, Wofsy M. Prognosis and natural history of Pneumocystis carinii pneumonia: indicators for early and late survival . In: Proceedings of the Third International Conference on AIDS; June 1-5,1987; Washington, DC . Abstract.
Drug Evaluations . 6th ed. Chicago, Ill: American Medical Association; 1986;.
Frenkel JK, Good JT, Shultz JA. Latent Pneumocystis infection of rats, relapse and chemotherapy . Lab Invest . 1966;;15:1559-1577.
Ivady G, Paldy L. Roentgenologic diagnosis of interstitial plasma cell pneumonia in infancy . Natl Cancer Inst Monogr .
(October)
1976;;43:99-119.
Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency . N Engl J Med . 1981;;305:1425-1431.
Clement M. Opportunistic infections, AIDS-associated malignancies and their management . In: Raposa N, ed. HIV Infection and Disease: Monographs for Physicians and Other Health Care Workers . Chicago, Ill: American Medical Association; 1990;:145-162.
Sands M, Kron MA, Brown RB. Pentamidine: a review . Rev Infect Dis . 1985;;7:625-634.
Donnelly H, Bernard EM, Rothkotter H, Gold JW, Armstrong D. Distribution of pentamidine in patients with AIDS . J Infect Dis . 1988;;157:985-989.
Waldman RH, Pearce DE, Martin RA. Pentamidine isethionate levels in lungs, livers, and kidneys of rats after aerosol or intramuscular administration . Am Rev Respir Dis . 1973;;108:1004-1006.
Debs RJ, Blumenfeld W, Brunette EN, et al. Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats . Antimicrob Agents Chemother . 1987;;31:37-41.
Montgomery AB, Debs RJ, Luce JM, et al. Selective delivery of pentamidine to the lung by aerosol . Am Rev Respir Dis . 1988;;137:477-478.
Conte JE, Golden JA. Concentrations of aerosolized pentamidine in bronchoalveolar lavage systemic absorption and excretion . Antimicrob Agents Chemother . 1988;;32:1490-1493.
Leoung GS, Montgomery AB, Abrams DA, Korkery K, Wardlaw L, Feigal DW. Aerosol pentamidine for Pneumocystis carinii pneumonia (PCP): a randomized trial of 439 patients . In: Proceedings of the Fourth International AIDS Conference; June 13-16,1988; Stockholm, Sweden. Book 1 , p 419. Abstract.
Leoung GS, Montgomery AB, McGinty E, Feigal DW, Lympho Med Consortium Investigators. Double-blinded randomized trial of aerosol pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 78.
Leoung GS, Montgomery AB, Abrams DI, et al. Aerosol pentamidine for Pneumocystis carinii pneumonia prophylaxis: a 3-arm randomized trial . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TB03.
NebuPent (Pentamidine Isethionate) Product Monograph . Rosemont, Ill: Lymphomed; 1989;:12-14.
Montaner JSG, Lawson L, Faultz J, et al. Aerosolized pentamidine in the secondary prophylaxis of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a report from the Canadian Cooperative Trial . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 54.
Girard PM, Landman R, Gaudebout C, et al. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients . Lancet . 1989;:1;1348-1352.
Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I . N Engl J Med . 1990;;322:161-165.
Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency Virus (HIV) infection . Ann Intern Med . 1989;;111:223-231.
Nightingale SD, Ferguson RS, Pounders SM, Jockush JB, Robertson KJ. A clinical experience with aerosolized pentamidine . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract TBP 56.
Weisman J, Paulsen YJ, Rogalsky E, et al. Inhaled pentamidine as primary prophylaxis in a high risk group—continuing experience . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 63.
Bernard EM, Dickmeyer MS, Schmitt H, Armstrong D. Long term safety and effectiveness of aerosol pentamidine for prevention of Pneumocystis carinii pneumonia . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract TROD 53.
Montgomery AB, Debs RJ, Luce JM, et al. Aerosolized pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome . Lancet . 1987;;2:480-483.
Armstrong D, Bernard E. Aerosol pentamidine . Ann Intern Med . 1988;;109:852-854.
Berger TG, Tappero JW, Leoung GS, Jacobson MA. Aerosolized pentamidine and cutaneous eruptions . Ann Intern Med . 1989;;110:1035-1036.
Martinez CM, Romanelli A, Mullen MP, Lee M. Spontaneous pneumothoraces in AIDS patients receiving aerosolized pentamidine . Chest . 1988;;94:1317-1318.
Leoung GS, Wardlaw L, Montgomery AB, Abrams DI, Feigal DW, and the SF County Community Consortium. Pneumothorax in patients receiving aerosol pentamidine for Pneumocystis carinii pneumonia prophylaxis . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 76.
Newsome GS, Ward DJ, Pierce PF. Spontaneous pneumothorax in AIDS patients on prophylactic aerosolized pentamidine . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract MBP 208.
Scannell KA. Atypical presentation of Pneumocystis carinii pneumonia in a patient receiving inhalational pentamidine . Am J Med . 1988;;85:881-884.
Camus F, dePicciotto C, Lepretre A, Landman R, Girard PM, Saimot AG. Effects des aerosols prophylactiques de Pentamidine sur la function respiratoire à moyen terme . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract TBO 2.
Sunderam G, McDonald RJ, Maniatis T, Oleske J, Kapila R, Reichman LB. Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS) . JAMA . 1986;;256:362-366.
Chaisson RE, Schecter BF, Thener CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy and survival . Am Rev Respir Dis . 1987;;136:570-574.
Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection . N Engl J Med . 1989;;320:545-550.
Advisory Committee for the Elimination of Tuberculosis (ACET). Tuberculosis and human immunodeficiency virus infection: Recommendations . MMWR . 1989;;38:236-250.
McDiakmid MA, Kram DJ. Aerosolised pentamidine and public health . Lancet . 1989;;2:863-864.
Smaldone GC, Perry RJ, Deutsch DG. Characteristics of nebulizers used in the treatment of Pneumocystis carinii pneumonia . J Aerosol Med . 1988;;1:113-126.
Corkery KJ, Luce JM, Montgomery AB. Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia: an update . Respir Care . 1988;;33:676-685.
Thomas S, O'Doherty M, Page C, Barlow D, Croft D, Bateman N. Absolute pulmonary deposition of nebulized pentamidine isethionate . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract TBP 57.
O'Doherty MJ, Thomas S, Page C, et al. Differences in relative efficiency of nebulizers for pentamidine administration . Lancet . 1988;;2:1283-1286.
Smith D, Erskine D, Steele J, Hills D, Gazzard BG. Comparison of nebulizer efficiency for aerosolized pentamidine . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 64.
Keyes C, Rodgers P, Marte C, Wolbert J, Kelly J, Ribble D. Successful chemoprophylaxis of PCP by postural inhalation and low dose aerosolized pentamidine . In: Proceedings of the Fifth International Conference on AIDS; June 4-9,1989; Montreal, Canada . Abstract TBP 51.
Ernst J, DiPasquale L, Sy ER, Rubinstein D. Prophylactic inhalation of pentamidine in patients with HIV disease . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 55.
Ruf B, Pohle HO, Schurmann D. Primary and secondary prophylaxis against Pneumocystis carinii pneumonia with Fansidar . In: Proceedings of the Fifth International Conference on AIDS; June 4-9, 1989; Montreal, Canada . Abstract TBP 21.
Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS . JAMA . 1988;;259:1185-1189.